1. Home
  2. VIGL

VIGL

Vigil Neuroscience Inc.

Logo Vigil Neuroscience Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

Founded: 2020 Country:
United States
United States
Employees: N/A City: WATERTOWN
Market Cap: 101.4M IPO Year: 2022
Target Price: $18.50 AVG Volume (30 days): 89.7K
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.13 EPS Growth: N/A
52 Week Low/High: $2.53 - $11.11 Next Earning Date: 05-08-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: